Targeted Medication Guidance for Lung Cancer

Name: Targeted Medication Guidance for Lung Cancer
Brand: CapitalBio Technology Co., Ltd.

This test detects SNV, InDel, CNV and gene rearrangement of 12 genes closely related to lung cancer, covering FDA/NMPA drug instructions, NCCN guidelines recommendations and medication guidance with clear drug targets. It is mainly used for lung cancer targeted medication guidance and drug resistance monitoring.

Inquire Now

Features of Targeted Medication Guidance for Lung Cancer

Gene	Related Drugs
ALK	Crizotinib, Alectinib, Ceritinib, Brigatinib, Lorlatinib
BRAF	Dabrafenib + Trametinib, Dabrafenib, Vemurafenib
EGFR	Gefitinib, Erlotinib, Icotinib, Afatinib, Dacomitinib, Osimertinib, Erlotinib + Ramucirumab, Erlotinib + Bevacizumab
HER2(ERBB2)	Ado-Trastuzumab Emtansine
KRAS	EGFR TKI
MET	Capmatinib, Crizotinib
NTRK1/2/3	Larotrectinib, Entrectinib
PIK3CA	Alpelisib
RET	Selpercatinib, Pralsetinib, Cabozantinib, Vandetanib
ROS1	Entrectinib, Crizotinib, Ceritinib, Lorlatinib

Applicable Population of Targeted Medication Guidance for Lung Cancer

For newly diagnosed patients with lung cancer, treatment plans can be formulated according to molecular typing.
For patients in need of targeted drugs, targeted drugs can be guided based on mutation information.
For drug-resistant patients, drug-resistant mutations can be monitored to guide the adjustment of treatment regimens.

Specification of Targeted Medication Guidance for Lung Cancer

Sample types	Venous blood/Tissue/ Paraffin section
TAT	10 days

Products

Related Solutions for Anti-cancer Therapy Documents

CapitalBio Solution of Detection of Tuberclosis

Click To View

Monkeypox Virus Nucleic Acid Detection Kit Brochure

Click To View